Chromosomal analysis or the study of genetic differences in patients previously untreated with AML, ALL, MDS or MM may be helpful in the diagnosis and classification of disease. It may also improve the ability to predict the course of disease and the selection of therapy. Institutions must have either an Alliance-approved cytogeneticist or an agreement from an Alliance-approved main member cytogenetics laboratory to enroll a patient on CALGB 8461. The Alliance Approved Institutional Cytogeneticists list is posted on the Alliance for Clinical Trials in Oncology website.

Population

Patient population from the clinical oncology research community including academic institutions, hospitals and clinics.

Brief Title

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma

Official Title

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma: Companion to CALGB Treatment Studies For Previously Untreated Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS) or Multiple Myeloma (MM) Patients

Brief Summary

Chromosomal analysis or the study of genetic differences in patients previously untreated <br /> with AML, ALL, MDS or MM may be helpful in the diagnosis and classification of disease. It <br /> may also improve the ability to predict the course of disease and the selection of therapy. <br /> Institutions must have either an Alliance-approved cytogeneticist or an agreement from an <br /> Alliance-approved main member cytogenetics laboratory to enroll a patient on CALGB 8461. The <br /> Alliance Approved Institutional Cytogeneticists list is posted on the Alliance for Clinical <br /> Trials in Oncology website.